You are here: Home ยป Archives for healthcare

Policymakers should recognise #SelfCareIsHealthcare in campaign bid to address global health challenges

  • Self–care describes the role of individuals in preventing disease, promoting and maintaining their mental and physical health, and actively participating in their healthcare
  • A wealth of evidence demonstrates the significant value of self–care to individuals, health systems, society and the economy

  • Despite this, self–care is not universally viewed or understood as a healthcare intervention and there is unequal access to self–care interventions around the world

GENEVA, July 24, 2024 (GLOBE NEWSWIRE) — The Global Self–Care Federation (GSCF) is urgently calling upon policymakers and health leaders worldwide to embrace self–care as an essential component of healthcare, by ensuring it is fully integrated into national health systems and policies, as part of this year’s International Self–Care Day on July 24.

The concept of self–care was first recognised by the World Health Organization (WHO) in 1983. It describes the role of individuals in preventing disease, promoting and maintaining their mental and physical health, and actively participating in their healthcare. Examples of self–care practices include medicines, devices, diagnostics digital tools as well as healthy lifestyle choices.

As health systems worldwide continue to face a range of challenges – from increased demand on services, to inequity in access to healthcare – evidence shows that self–care can:

  • avert an estimated 3.9 million premature deaths each year, through physical activity alonei
  • save nearly $120 billion each year for global healthcare systems and, therefore, national economiesii
  • improve the autonomy and agency of disadvantaged groups, including women and girls, in managing their own healthiii
  • provide a legitimate tool in the pursuit of universal health coverageiv

Judy Stenmark, Director General of GSCF, said: “Right now, health systems around the world are struggling, long–term ill health is on the rise, health disparities are growing and the impact of COVID–19 is still being felt. Addressing these requires new approaches and strategies, including evidence–based self–care – to achieve sustainable health services fit for the future.

“Our ‘Self–care is healthcare’ campaign is all about fuelling the movement for self–care to be recognised as an integral part of healthcare. It aims to drive greater awareness and recognition of the potential of self–care to people and policymakers across the world. At GSCF, we firmly believe that everyone benefits when there is a greater choice of healthcare options and more accessible entries to care.”

Building on this year’s International Self–Care Day, GSCF is urging members and campaigners to rally behind the #SelfCareIs movement. This initiative aims to educate global audiences about the critical link between self–care and healthcare. It also encourages engagement with local policymakers and healthcare providers to call on them to put in place plans for the urgent integration of self–care into the healthcare delivery continuum.

To find out more and to get involved, please visit the campaign website: https://self–care–is–healthcare.org/.

Notes to editors

WHO definition of self–care
Self–care is the ability of individuals, families and communities to promote health, prevent disease, maintain health, and cope with illness and disability with or without the support of a health worker.

About The Global Self–Care Federation
The Global Self–Care Federation represents associations and manufacturers in the self–care industry, promoting sustainable and better global health outcomes for all. The Global Self–Care Federation is the go–to source of information for the self–care industry. We work closely with our members and relevant stakeholder groups to deliver better choice, better care and better value. By placing the benefits of self–care at the heart of what we do, promoting industry transparency, and supporting the regulated use of health data, we ensure that self–care continues to play its increasingly vital role in sustainable healthcare, worldwide. For more information please visit: www.selfcarefederation.org.

About International Self–Care Day
International Self–Care Day is held annually on July 24th (7/24), to highlight that the benefits of self–care are experienced 24 hours a day, seven days a week. International Self–Care Day raises awareness of the value of self–care and the benefit that effective self–care can bring to both individuals and healthcare systems as a vital foundation of health.

i https://www.who.int/news–room/fact–sheets/detail/self–care–health–interventions#:~:text=Self%2Dcare%20is%20the%20ability,a%20health%20or%20care%20worker.
ii https://www.selfcarefederation.org/ecosoc–report
iii https://www.nature.com/articles/s41591–024–02844–8#Sec19
iv https://www.who.int/health–topics/self–care#tab=tab_1

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/b4ee215a–f0b4–4837–a280–90659dcf5aa5


GLOBENEWSWIRE (Distribution ID 1000982941)

CSL Behring Announces First Two Patients Treated with HEMGENIX® (etranacogene dezaparvovec) Gene Therapy for Hemophilia B in Europe

MARBURG, Germany, July 04, 2024 (GLOBE NEWSWIRE) — Global biotechnology leader CSL Behring (ASX: CSL) today announced that two hemophilia B patients were treated with the gene therapy HEMGENIX® (etranacogene dezaparvovec) at Hemophilia Treatment Centers in France. This milestone achievement makes HEMGENIX® the first gene therapy administered as a treatment in a real–world setting for hemophilia B in Europe.

HEMGENIX® is the first one–time gene therapy approved in Europe for the treatment of adults with severe and moderately severe hemophilia B, an inherited bleeding disorder caused by the lack of Factor IX (a protein needed to produce blood clots to stop bleeding). It is used in adults without a history of Factor IX inhibitors.1

Following European Commission approval, HEMGENIX® was the first ever therapy to be granted Direct Access in France2, thus enabling the first patients to be treated in Europe outside of the clinical program.

Though effective, current therapies can be time intensive and require regular treatment that can have a substantial impact on a patient’s daily life.3 HEMGENIX® offers a one–time treatment, allowing people living with hemophilia B to produce their own Factor IX, which can lower the risk of bleeding.4

“Only a few decades ago, gene therapy for hemophilia was a distant concept, which has now become reality. Accordingly, the first two patients treated with HEMGENIX® since receiving European approval is a major accomplishment and a testament to the joint commitment of the hemophilia B community, as well as the access and reimbursement authorities, in bringing innovative therapies to patients,” said Dr Lutz Bonacker SVP and General Manager, CSL Behring Commercial Operations Europe. “This milestone has been made possible by the innovative Direct Access scheme adopted in France, allowing patients to benefit from early access to pioneering treatments. We are encouraged to see increasing access to gene therapies in European countries and are fully committed to ensuring that access to potentially life–changing treatment continues.”

HEMGENIX® was granted conditional marketing authorisation by the European Commission (EC) for the European Union and European Economic Area in February 2023, following approval from the U.S. Food and Drug Administration (FDA) in November 2022. It has also been approved by Health Canada, the United Kingdom's Medicines and Healthcare products Regulatory Agency (MHRA), Switzerland’s Swissmedic and Australia’s Therapeutic Goods Administration (TGA).

The multi–year clinical development of HEMGENIX® was led by uniQure and sponsorship of the clinical trials transitioned to CSL after it licensed global rights to commercialise the treatment.

About Hemophilia B

Hemophilia B is a life–threatening rare disease. People with the condition are particularly vulnerable to bleeds in their joints, muscles, and internal organs, leading to pain, swelling, and joint damage. Current treatments for moderate to severe hemophilia B include life–long prophylactic infusions of factor IX to temporarily replace or supplement low levels of the blood–clotting factor.  

About HEMGENIX®

HEMGENIX® is a gene therapy that reduces the rate of abnormal bleeding in eligible people with hemophilia B by enabling the body to continuously produce factor IX, the deficient protein in hemophilia B. It uses AAV5, a non–infectious viral vector, called an adeno–associated virus (AAV). The AAV5 vector carries the Padua gene variant of Factor IX (FIX–Padua) to the target cells in the liver, generating factor IX proteins that are 5x–8x more active than normal. These genetic instructions remain in the target cells, but generally do not become a part of a person’s own DNA. Once delivered, the new genetic instructions allow the cellular machinery to produce stable levels of factor IX.

About the Pivotal HOPE–B Trial

The pivotal Phase III HOPE–B trial is an ongoing, multinational, open–label, single–arm study to evaluate the safety and efficacy of HEMGENIX®. Fifty–four adult hemophilia B patients classified as having moderately severe to severe hemophilia B and requiring prophylactic factor IX replacement therapy were enrolled in a prospective, six–month or longer observational period during which time they continued to use their current standard of care therapy to establish a baseline Annual Bleeding Rate (ABR). After the six–month lead–in period, patients received a single intravenous administration of HEMGENIX® at the 2×10^13 gc/kg dose. Patients were not excluded from the trial based on pre–existing neutralizing antibodies (NAbs) to AAV5.

A total of 54 patients received a single dose of HEMGENIX® in the pivotal trial, with 52 patients completing at least three years of follow–up. The primary endpoint in the pivotal HOPE–B study was ABR 52 weeks after achievement of stable factor IX expression (months 7 to 18) compared with the six–month lead–in period. For this endpoint, ABR was measured from month seven to month 18 after infusion, ensuring the observation period represented a steady–state factor IX transgene expression. Secondary endpoints included assessment of factor IX activity.

No serious treatment–related adverse reactions were reported. One death resulting from urosepsis and cardiogenic shock in a 77–year–old patient at 65 weeks following dosing was considered unrelated to treatment by investigators and the company sponsor. A serious adverse event of hepatocellular carcinoma was determined to be unrelated to treatment with HEMGENIX® by independent molecular tumour characterization and vector integration analysis. No inhibitors to factor IX were reported. 

Long–term three–year data presented at the 17th Annual Congress of the European Association for Haemophilia and Allied Disorders (EAHAD) 2024 continue to reinforce the potential long–lasting efficacy and safety of HEMGENIX® and the ongoing benefit of this treatment for people living with hemophilia B.

About CSL
CSL (ASX:CSL; USOTC:CSLLY) is a global biotechnology company with a dynamic portfolio of lifesaving medicines, including those that treat hemophilia and immune deficiencies, vaccines to prevent influenza, and therapies in iron deficiency and nephrology. Since our start in 1916, we have been driven by our promise to save lives using the latest technologies. Today, CSL – including our three businesses: CSL Behring, CSL Seqirus and CSL Vifor – provides lifesaving products to patients in more than 100 countries and employs 32,000 people. Our unique combination of commercial strength, R&D focus and operational excellence enables us to identify, develop and deliver innovations so our patients can live life to the fullest. For inspiring stories about the promise of biotechnology, visit CSL.com/Vita. For more information about CSL, visit CSL.com.

Media Contacts
Stephanie Fuchs
Mobile: +49 151 584 388 60
Email: Stephanie.Fuchs@cslbehring.com

References

1 European Medicines Agency. First Gene therapy to treat haemophilia B. Available at: https://www.ema.europa.eu/en/news/first–gene–therapy–treat–haemophilia–b. [Accessed May 2024].
2 Republique Française. Légifrance: Article 62 of Law No. 2021–1754. Available at: https://www.legifrance.gouv.fr/jorf/id/JORFTEXT000048551003 [Accessed May 2024].
3 Leebeek, F & Miesbach, W. (2021) Gene therapy for haemophilia: a review on clinical benefit, limitations, and remaining issues. Blood. Vol 138, Issue 11. pp923–931.
4 Coppens M et al. Etranacogene dezaparvovec gene therapy for haemophilia B (HOPE–B): 24–month post–hoc efficacy and safety data from a single–arm, multicentre, phase 3 trial. The Lancet Haematology 2024; 11(4):E265–E275.


GLOBENEWSWIRE (Distribution ID 1000969961)

Standards Alliance Awards Inteleos Foundation to Expand Ultrasound Training in Kenya

ROCKVILLE, Md., June 21, 2024 (GLOBE NEWSWIRE) — The Inteleos Foundation, a public non–profit organization driving positive health outcomes through education in medical imaging, received a three–year, $180,000 subaward from the Standards Alliance Phase 2 (SA2) Program; a public private partnership between United States Agency for International Development (USAID) and the American National Standards Institute (ANSI), to fund an innovative ultrasound training program in Kenya.

The SA2 program implemented by ANSI aims to help increase the capacity of developing countries to implement accepted international best practices around National Quality Infrastructure (NQI) and prevent or remove non–tariff barriers, and stimulate economic growth, while also preserving and expanding markets for U.S. businesses.

In collaboration with Inteleos, a non–profit certification organization, the activity will support the Inteleos Foundation’s efforts to establish standardized ultrasound education and certification at a national scale to increase access to essential ultrasound services across Kenya. This initiative aligns with SA2's focus on improving maternal health outcomes through expanding access to point–of–care ultrasound, including developing training curriculum and certification for midwives and nurses.

“We are grateful for the generous support of ANSI and USAID. The subaward will allow us to make significant strides in building the ultrasound workforce capacity in Kenya,” said Pamela Ruiz, chief business development officer at Inteleos. “This funding enables us, with local partners, to develop a standard level of proficiency and certification for primary maternal clinicians for high–quality ultrasound care, ultimately improving maternal and fetal health outcomes.”

The Standards Alliance funding will be distributed over three years to fund the following key initiatives:

  • Establish a national task force to recommend policies for ultrasound practice by nurses, midwives and maternal clinicians
  • Develop a standardized ultrasound curriculum in partnership with educational institutions
  • Implement ultrasound training and certification programs, targeting 90 trainees in the first year
  • Expand ultrasound training to reach more healthcare providers across multiple regions
  • Evaluate the impact of training on clinicians and patients
  • Develop a sustainable financing model to ensure program continuity

“Developing an activity to work in the health sector in Kenya was a natural fit under the Standards Alliance’s goals, and we are pleased to be working with Inteleos, as their expertise in the field will help improve maternal health in Kenya and foster development,” said Leslie McDermott, senior director for the International Development department at ANSI.

“The collaboration between USAID–ANSI’s Standards Alliance and Inteleos in Kenya is playing a vital role in helping our partner country achieve its development goals,” said Daniel Vazquez, USAID's senior standards specialist. “This work under the Standards Alliance exemplifies our Agency's ability to work in innovative ways with the U.S. private sector to achieve sustainable development results. Leveraging its expertise and localizing it within Kenyan partners is critical to our approach.”

Inteleos will work closely with the Kenyan Ministry of Health, healthcare facilities, academic institutions like Amref International University and professional associations to execute this comprehensive program, as well as the USAID local Mission in the country. The project aims to address the critical need for accessible and skilled ultrasound services, particularly in regions with high maternal mortality rates.

“For the five years Amref International University has actively trained on Point of Care Obstetric Ultrasound screening (OPOCUS), there is evidence that this is the gateway to mitigating risks that are associated with preventable maternal deaths in developing countries,” said Dr. Micah Matiang’i, principal investigator, OPOCUS training at the Amref International University.

The ultrasound training initiative in Kenya aligns with USAID's regional health priorities and commitment to strengthening healthcare systems and improving access to quality care highlighted in their Kenya Country Development Cooperation Strategy.

Learn more about the Inteleos Foundation and its global health initiatives.
Learn more about the Standards Alliance Phase 2 program.

About Inteleos
Inteleos™ is a non–profit organization that fuels the global health community to ensure access to quality care. Inteleos is the overarching governance and management organization for the American Registry for Diagnostic Medical Sonography® (ARDMS®) the Alliance for Physician Certification & Advancement™ (APCA™) and the Point–of–Care Ultrasound Certification Academy™ (PCA) which together represents more than 141,000 certified medical professionals throughout the world.

About the Inteleos Foundation
The Inteleos Foundation accelerates the global expansion of the mission–driven work of Inteleos, ARDMS, APCA and the POCUS Certification Academy through its philanthropic efforts.


GLOBENEWSWIRE (Distribution ID 9157628)

From Awareness to Action on Global Fatty Liver Day

Global Liver Institute Unites the Field in Times of Name Changes and New Treatments

WASHINGTON, June 13, 2024 (GLOBE NEWSWIRE) — Today marks the seventh annual Global Fatty Liver Day (formerly International NASH Day), led by Global Liver Institute (GLI) with the theme “Act Now, Screen Today.” This campaign underscores the crucial need for early identification and treatment of fatty liver disease to prevent its progression to chronic liver disease, cirrhosis, or cancer.

Fatty liver disease is now estimated to affect 1 in 3 adults worldwide, and its prevalence is increasing. Fatty liver disease during childhood, once unheard of, is also on the rise. Early detection and timely intervention, whether through lifestyle changes or medical treatments, are essential in stopping and even reversing the progression of the disease. “Act Now, Screen Today'' emphasizes that liver health is achievable, but action must begin immediately. Across the globe, partners are driving awareness and educational efforts and ensuring broader access to essential screenings and care.

Global Fatty Liver Day, observed annually on the second Thursday of June, is a rallying cry for collective action to address the growing prevalence of fatty liver disease, the most common liver disease worldwide. “Act Now, Screen Today” reminds everyone that liver health is within reach. Here are specific actions you can take today:

  • Take advantage of liver health screening events happening globally to get assessed for fatty liver disease or schedule a check–up with your doctor, especially if you are managing closely associated metabolic conditions like obesity or diabetes
  • Increase physical activity, as maintaining an active lifestyle can improve liver health
  • Learn about fatty liver disease and its risk factors to take proactive steps towards prevention and management yourself or learn more about the latest research and guidelines for your patients.

With a robust pipeline of pharmaceutical treatments that address diverse mechanisms of action in progress, it is important to identify individuals’ position within the progression of fatty liver disease so that they are poised to receive the most appropriate care possible. Notably, pharmaceutical treatments are available (for certain groups with advanced disease) in two countries, the United States (resmetirom) and India (saroglitazar).

“As a community, we stand at a critical time for the broader global health system to act now to support patients,” shares Donna R. Cryer, JD, Founder and CEO of GLI. “As pharmaceutical treatment options gain approval in different geographies, health payers and systems must listen to the call from global advocates and not place undue obstacles to care – whether that be required biopsy, ambiguous lifestyle requirements, or other hurdles – so that patients are able to access the care they require, no matter who or where they are.”

Recognizing the importance of early detection, a diverse range of partners, including healthcare providers, patient advocacy groups, and community organizations, have joined forces to “Act Now, Screen Today” and launch screening events around the world. From Chile to Nigeria to the Netherlands, the Philippines, and beyond, these events aim to raise awareness, provide education, and offer screening services to individuals at risk of fatty liver disease or the providers who care for them. Global Fatty Liver Day activities are driving positive change at the grassroots level.

“Global Fatty Liver Day is an urgent call–to–action to unite our global efforts to confront the scourge of fatty liver disease,” shares Cat Evans, Director of Program Operations at GLI. “We must act now. By working together, we have the power to create significant change in preventing and managing this pressing health issue through our collaborative efforts.”

Although the challenge of fatty liver disease to the well–being of communities around the globe is great, the power of locally–rooted, collective efforts can turn the tide towards positive change by heightening awareness, equipping people and their healthcare providers with prevention and management tools, expanding understanding of the disease through research, and protecting future liver health through effective policies.

About Global Liver Institute

Global Liver Institute (GLI) is a 501(c)3 nonprofit organization founded in the belief that liver health must take its place on the global public health agenda commensurate with the prevalence and impact of liver illness. GLI promotes innovation, encourages collaboration, and supports the scaling of optimal approaches to help eradicate liver diseases. Operating globally, GLI is committed to solving the problems that matter to liver patients and equipping advocates to improve the lives of individuals and families impacted by liver disease. Follow GLI on Facebook, Instagram, LinkedIn, and YouTube, or visit www.globalliver.org. GLI is the host of Global Fatty Liver Day.

Christine Maalouf 
Global Liver Institute
cmaalouf@globalliver.org


GLOBENEWSWIRE (Distribution ID 9153607)

King Faisal Specialist Hospital & Research Centre Wins 2024 Tech Impact Award from VBHC

RIYADH, Saudi Arabia, May 16, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital & Research Centre (KFSHRC) has achieved a significant milestone by winning the 2024 Tech Impact Award, a prestigious recognition presented by the Value–Based Health Care Centre Europe. This accolade, awarded for its pioneering Home Hemodialysis (HHD) initiative, underscores KFSHRC's unwavering commitment to comprehensive healthcare and further cement its position as a global leader in the healthcare industry.

The award–winning initiative is a testament to KFSHRC's patient–centric approach, designed to address the unique needs of kidney patients with advanced medical conditions, physical disabilities, and mobility challenges. This comprehensive system of continuous and supportive care, delivered in the comfort of their homes, not only ensures the highest standards of safety and comfort but also significantly improves their quality of life.

Dr. Wael Habhab, Chairman of the Internal Medicine Department at KFSHRC in Jeddah and a leading physician for the Home Hemodialysis initiative, stated, “The initial outcomes of the initiative revealed a substantial reduction in emergency room visits and hospital admissions, as well as lower re–hospitalization rates.” He also confirmed that the initiative has greatly alleviated the burden of managing medications for bone and mineral diseases associated with chronic kidney failure, alongside a decreased need for intravenous medication injections.

The award is granted to healthcare institutions that offer innovative solutions, contribute to tangible outcomes, reduce costs, and enhance patient value, all within a framework of genuine engagement between healthcare providers and patients, redefining healthcare standards to provide exceptional, patient–centered services.

It is noteworthy that KFSHRC stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating the standards of healthcare worldwide.

King Faisal Specialist Hospital & Research Centre has been ranked first in the Kingdom and 20th globally, in the list of the world’s top 250 healthcare institutions for the second consecutive year and recognized as the most–valuable healthcare brand in the Kingdom and the Middle East, according to 2024 Brand Finance rankings. Additionally, in the same year, it was ranked among the world's best hospitals by the prestigious Newsweek magazine.

For further information, please contact:
Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429
Mr. Abdullah Alown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/51181584–0ddf–46da–95b8–4332570c4d2e

 


GLOBENEWSWIRE (Distribution ID 9119253)

نظير مبادرته الرائدة في مجال غسيل الكلى المنزلي “التخصصي” يفوز بجائزة التأثير التقني من VBHC للعام 2024

الرياض, May 16, 2024 (GLOBE NEWSWIRE) — فاز مستشفى الملك فيصل التخصصي ومركز الأبحاث بجائزة التأثير التقني للعام 2024، المقدمة من مركز الرعاية الصحية القائمة على القيمة الأوربي (Value–Based Health Care Center Europe)، نظير مبادرته الرائدة في مجال غسيل الكلى المنزلي، التي تأتي في إطار التزام المستشفى بتقديم رعايةٍ صحية شاملة، لتضاف إلى قائمة نجاحات “التخصصي” المتواصلة محلياً وعالمياً

وتهدف المبادرة المتوجة بالجائزة، إلى تلبية احتياجات مرضى الكلى الذين يعانون من حالاتٍ مرضية متقدمة، وعجزٍ جسدي وصعوبات في الحركة، حيث تقدم لهم منظومة متكاملة من الرعاية المستمرة والداعمة، بما يتوافق مع بيئتهم لضمان أعلى معايير السلامة والراحة وجودة الخدمات للمرضى دون الحاجة إلى مغادرة منازلهم.

وقال الدكتور وائل حبحب، رئيس قسم الأمراض الباطنية بمستشفى الملك فيصل التخصصي ومركز الأبحاث بجدة وقائد مبادرة غسيل الكلى المنزلي: “أظهرت النتائج الأولية للمبادرة انخفاضاً ملحوظاً في عدد زيارات غرف الطوارئ والتنويم في المستشفى، وكذلك في معدلات إعادة دخول المستشفى”. مؤكداً تحقيق المبادرة انخفاضاً كبيراً في تحمل أعباء الأدوية المرتبطة بإدارة أمراض المعادن والعظام المرتبطة بمرض الفشل الكلوي المزمن، إلى جانب انخفاض الحاجة إلى حقن الأدوية عن طريق الوريد.

وتمنح الجائزة للمؤسسات الصحية التي تقدم حلول رعاية صحية مبتكرة تسهم في تحقيق نتائج ملموسة، وتخفيض التكاليف، وتعزيز القيمة المقدمة للمرضى، في إطارٍ من التواصل الحقيقي بين مقدم خدمات الرعاية الصحية والمريض، وهو ما يعد مفهوماً حديثاً يُعيد تعريف معايير الرعاية الصحية لتقديم خدمات استثنائية تتمحور حول المريض

يذكر أن مستشفى الملك فيصل التخصصي ومركز الأبحاث يُعد من بين أبرز المؤسسات الرائدة عالمياً في تقديم الرعاية الصحية التخصصية، ودفع عجلة الابتكار، ومركزاً متقدماً في البحوث والتعليم الطبي، كما يسعى لتطوير التقنيات الطبية، والارتقاء بمستوى الرعاية الصحية على مستوى العالم، وذلك بالشراكة مع كبرى المؤسسات المحلية والإقليمية والدولية لتحقيق خدمةٍ عالمية المستوى في المجالات السريرية والبحثية والتعليمية.

وصُنف مستشفى الملك فيصل التخصصي ومركز الأبحاث للسنة الثانية على التوالي بالمركز الأول على مستوى المملكة والـ 20 عالمياً ضمن قائمة أفضل 250 مؤسسة رعاية صحية حول العالم، والعلامة التجارية الصحية الأعلى قيمة في المملكة والشرق الأوسط، وذلك بحسب “براند فاينانس” (Finance Brand) لعام 2024، كذلك صُنف في ذات العام من بين المستشفيات الأفضل عالميا من قبل مجلة نيوزويك

For further information, please contact
Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429
Mr. Abdullah Alown, Media Coordination Officer, 0556294232

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/51181584–0ddf–46da–95b8–4332570c4d2e/ar 

 


GLOBENEWSWIRE (Distribution ID 9119253)

King Faisal Specialist Hospital and Research Centre Dá as Boas-Vindas ao Novo CEO Interino Durante Suas Transformações Estratégicas

RIADE, Arábia Saudita, May 14, 2024 (GLOBE NEWSWIRE) — O King Faisal Specialist Hospital and Research Centre (KFSH&RC) nomeou recentemente o Dr. Björn Zoéga como CEO Interino, confirmando o seu empenho em promover e incentivar a excelência no cuidado da saúde. O Dr. Zoéga, conhecido por sua vasta experiência em gestão e políticas de saúde, se une a uma equipe dedicada em um momento em que o hospital continua a impulsionar iniciativas estratégicas importantes.

O KFSH&RC, líder em pesquisa médica e serviços clínicos, continua a atrair experiência global para reforçar sua visão de excelência em saúde. Com o envolvimento do Dr. Zoéga, o hospital dá seguimento à sua estratégia de transformação digital que visa aprimorar a eficiência operacional e aperfeiçoar o atendimento ao paciente. Sua experiência na promoção de colaborações internacionais, evidenciada no seu antigo cargo de presidente da European University Hospital Alliance (EUHA) e com as iniciativas como a Join4ATMP, que visa promover o acesso a terapias inovadoras, alinha ainda mais os serviços do KFSH&RC às tendências globais de saúde.

Os principais projetos do KFSH&RC incluem a implantação de tecnologias digitais avançadas para agilizar o processo de atendimento ao paciente, adoção de modelos de atendimento inovadores e atualização das instalações. Esses esforços estratégicos visam aumentar o acesso aos serviços médicos e facilitar uma melhor comunicação, refletindo a dedicação do KFSH&RC em estabelecer novos padrões de saúde.

As contribuições anteriores do Dr. Zoéga no Karolinska University Hospital, que é o segundo melhor da Europa e o sétimo do mundo de acordo com o 2024 World's Best Hospitals da revista Newsweek, onde ele cultivou uma cultura de aprendizagem contínua e colaboração entre profissionais de saúde, alinham–se bem com os objetivos do KFSH&RC. O seu papel na promoção de programas como o EUCARE e na facilitação do intercâmbio de enfermeiros de cuidados intensivos em toda a Europa durante crises melhorou significativamente o desenvolvimento do pessoal e apoiou o objetivo do seu hospital anterior de atrair os melhores talentos – um princípio espelhado na jornada de transformação do KFSH&RC. Com o Dr. Zoéga contribuindo para a liderança, o KFSH&RC está pronto para promover seu papel como ator fundamental na formação do futuro dos cuidados de saúde na Arábia Saudita.

Sobre o King Faisal Specialist Hospital and Research Centre :

O King Faisal Specialist Hospital & Research Centre é dos líderes globais de prestação de cuidados de saúde especializados, condução de inovação, e um hubs avançado de pesquisa e educação médica. Por meio de parcerias estratégicas com proeminentes instituições locais, regionais e internacionais, o hospital se dedica ao avanço de tecnologias médicas e elevação dos padrões de cuidado da saúde em todo o mundo.

O hospital conquistou sua posição como marca líder no setor de saúde em todo o Reino e Oriente Médio, marcando seu segundo ano consecutivo como a marca de saúde mais valiosa. Ele ocupa o 9º lugar no Reino e o 28º no Oriente Médio. O hospital se distingue como o único hospital do mundo a ser listado entre as 10 principais marcas do seu país, de acordo com dois relatórios da “Brand Finance” sobre as 50 marcas mais valiosas da Arábia Saudita e as 150 marcas mais valiosas do Oriente Médio em 2024.

Devido aos programas de transformação e à Vision 2030 do Reino, lançados por Sua Alteza Real o Príncipe Herdeiro e pelo Primeiro–Ministro – que Deus o proteja – para aumentar a liderança do Reino no setor global de saúde, o KFSH&RC surgiu como um dos principais Centros Médicos Acadêmicos do Oriente Médio e da África. Ele permaneceu em 20º lugar no mundo pelo segundo ano consecutivo em 2024, de acordo com o “Brand Finance”. Além disso, ele foi classificado entre os melhores hospitais do mundo em 2024 pela revista americana “Newsweek”.

Para mais informações, contate:

Sr. Essam AlZahrani, Dirigente Interino de Assuntos de Mídia, 0555254429

Sr. Abdullah Alown, Editor Sênior de Mídia, 0556294232

Foto deste comunicado disponível em https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605–9a75–41cb–8947–81c858209621


GLOBENEWSWIRE (Distribution ID 9117305)

En pleine transformation stratégique, le King Faisal Specialist Hospital and Research Centre accueille un nouveau directeur général adjoint

RIYAD, Arabie saoudite, 14 mai 2024 (GLOBE NEWSWIRE) — L’hôpital spécialisé et centre de recherche King Faisal, ou KFSH&RC pour King Faisal Specialist Hospital and Research Centre a récemment accueilli le Dr Björn Zoéga en tant que directeur général adjoint. Cette nomination souligne son engagement en faveur de la promotion et du maintien de l’excellence en matière de santé. Le Dr Zoéga, réputé pour sa vaste expérience en gestion et sa maîtrise des politiques de la santé, rejoint une équipe dédiée à l’heure où l’hôpital continue de piloter des initiatives stratégiques clés.

Le KFSH&RC, leader de la recherche médicale et des services cliniques, continue d’attirer des ressources expertes à l’échelle mondiale pour renforcer sa mission d’excellence en matière de santé. L’arrivée du Dr Zoéga fait avancer la stratégie de transformation numérique de l’hôpital, conçue pour doper son efficacité opérationnelle et améliorer les soins prodigués aux patients. Son expertise dans la promotion de collaborations internationales, comme en témoigne son ancien rôle de président de l’Alliance des hôpitaux universitaires européens (ou « EUHA » pour European University Hospital Alliance) et sa participation à des initiatives telles que JOIN4ATMP, visant à promouvoir l’accès à des thérapies innovantes, concourent à un meilleur alignement des services du KFSH&RC sur les tendances mondiales en matière de santé.

Les projets clés de l’hôpital prévoient le déploiement de technologies numériques avancées pour standardiser les mécanismes propres aux soins prodigués aux patients, l’adoption de nouveaux modèles de soins et la modernisation de ses installations. Ces efforts stratégiques visent à améliorer l’accès aux services médicaux et à induire une meilleure communication à leur propos, et traduisent l’engagement du KFSH&RC envers l’établissement de nouvelles normes en matière de santé.

Les précédentes contributions du Dr Zoéga à l’hôpital universitaire Karolinska, placé au deuxième rang européen et au septième rang mondial du classement 2024 des meilleurs hôpitaux du monde établi par Newsweek, ont joué en faveur d’une culture d’apprentissage continu et de collaboration entre les professionnels de santé. Elles répondent ainsi parfaitement aux objectifs du KFSH&RC. Son rôle dans la promotion de programmes comme EUCARE et sa participation au développement des échanges intra Europe d’infirmières en soins intensifs en période de crise a considérablement renforcé le développement du personnel et appuyé l’objectif de son précédent hôpital d’attirer les meilleurs talents ; un principe reflété dans le parcours de transformation du KFSH&RC. Maintenant que le Dr Zoéga prend part au leadership du KFSH&RC, l’établissement s’apprête à renforcer son rôle d’acteur clé dans le façonnage de la santé de demain en Arabie saoudite.

À propos du King Faisal Specialist Hospital and Research Centre :

Le King Faisal Specialist Hospital & Research Centre fait partie des leaders mondiaux en matière de soins de santé spécialisés, et d’innovation, servant de centre de formation et de recherche médicale avancée. Grâce à des partenariats stratégiques avec d’éminents établissements locaux, régionaux et internationaux, l’hôpital se consacre à l’avancement des technologies médicales et à l’élévation des normes de soins de santé dans le monde entier.

L’hôpital a conforté sa position de leader du secteur de la santé en Arabie saoudite et au Moyen–Orient, en se voyant décerner, pour la deuxième année consécutive, le titre de marque de santé la plus valorisée. Il se classe 9e du royaume et 28e au Moyen–Orient. L’hôpital se distingue en étant le seul hôpital du monde à figurer au top 10 des marques de son pays, comme le soulignent deux rapports de « Brand Finance » consacrés aux 50 meilleures marques d’Arabie saoudite et aux 150 meilleures marques du Moyen–Orient en 2024.

En raison des programmes de transformation et du projet royal « Saudi Vision 2030 » initié par Son Altesse Royale le Prince Héritier et Premier Ministre — que Dieu le préserve — pour renforcer le leadership du royaume dans le secteur de la santé mondiale, le KFSH&RC est devenu un centre médical universitaire de première importance dans la région MENA. En 2024, il s’est classé au 20e rang mondial pour la deuxième année consécutive selon « Brand Finance », et s’est également distingué parmi les 250 meilleurs hôpitaux du monde selon le magazine américain « Newsweek » cette même année.

Pour tout complément d’information, veuillez contacter :

M. Essam AlZahrani, Responsable des affaires médiatiques, 0555254429

M. Abdullah Alown, Coordinateur médias, 0556294232

Une photo accompagnant ce communiqué est disponible à l’adresse suivante : https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605–9a75–41cb–8947–81c858209621


GLOBENEWSWIRE (Distribution ID 9117305)

King Faisal Specialist Hospital and Research Centre begrüßt neuen stellvertretenden CEO inmitten strategischer Umstrukturierungen

RIAD, Saudi–Arabien, May 14, 2024 (GLOBE NEWSWIRE) — Das King Faisal Specialist Hospital and Research Centre (KFSH&RC) hat vor kurzem Dr. Björn Zoéga als stellvertretenden CEO willkommen geheißen – eine Ernennung, die das Engagement des Krankenhauses zur Förderung von Spitzenleistungen im Gesundheitswesen unterstreicht. Dr. Zoéga, der für seine umfassende Erfahrung in den Bereichen Gesundheitsmanagement sowie Gesundheitspolitik bekannt ist, stößt zu einem engagierten Team, mit dem das Krankenhaus weiterhin wichtige strategische Initiativen vorantreibt.

Das KFSH&RC, eine führende Einrichtung im Bereich der medizinischen Forschung und der klinischen Dienstleistungen, zieht weiterhin weltweite Expertise an, um seine Vision von Spitzenleistungen im Gesundheitswesen zu untermauern. Unter der Mitwirkung von Dr. Zoéga verfolgt das Krankenhaus eine digitale Transformationsstrategie, die darauf abzielt, die betriebliche Effizienz zu steigern und die Patientenversorgung zu verbessern. Seine Erfahrung in der Stärkung internationaler Kooperationen, die er in seiner früheren Rolle als Präsident der European University Hospital Alliance (EUHA) und durch Initiativen wie JOIN4ATMP zur Förderung des Zugangs zu innovativen Therapien unter Beweis gestellt hat, trägt ebenfalls dazu bei, die Dienstleistungen des KFSH&RC an globale Trends im Gesundheitswesen anzupassen.

Zu den wichtigsten Projekten des KFSH&RC gehören der Einsatz fortschrittlicher digitaler Technologien zur Rationalisierung der Patientenversorgung, die Einführung innovativer Pflegemodelle und die Verbesserung der Ausstattung der Einrichtungen. Diese strategischen Bemühungen sollen den Zugang zu medizinischen Dienstleistungen verbessern sowie eine bessere Kommunikation ermöglichen und zeugen vom Engagement des KFSH&RC, neue Standards im Gesundheitswesen zu setzen.

Auch Dr. Zoégas früheres Wirken am Karolinska–Universitätskrankenhaus, das im Newsweek–Ranking „2024 World's Best Hospitals“ als das zweitbeste in Europa und das siebtbeste weltweit eingestuft wurde und wo er sich für eine Kultur des kontinuierlichen Lernens und der Zusammenarbeit unter den Fachkräften des Gesundheitswesens einsetzte, deckt sich mit den Zielen des KFSH&RC. Seine Rolle bei der Förderung von Programmen wie EUCARE und der Erleichterung des europaweiten Austauschs von Intensivpflegekräften in Krisensituationen hat die Personalentwicklung erheblich verbessert und das Ziel seines früheren Krankenhauses, Spitzenkräfte zu gewinnen, unterstützt – ein Prinzip, das sich auch in der angestrebten Transformation des KFSH&RC widerspiegelt. Unter der Leitung von Dr. Zoéga wird das KFSH&RC seine Rolle als zentraler Akteur bei der Gestaltung der Zukunft der Gesundheitsversorgung in Saudi–Arabien weiter ausbauen.

Über das King Faisal Specialist Hospital and Research Centre:

Das King Faisal Specialist Hospital & Research Centre ist weltweit führend in der Bereitstellung spezialisierter Gesundheitsversorgung, treibt Innovationen voran und dient als Zentrum für medizinische Forschung und Ausbildung. Durch strategische Partnerschaften mit prominenten lokalen, regionalen und internationalen Institutionen engagiert sich das Krankenhaus für die Weiterentwicklung medizinischer Technologien und die Anhebung der Gesundheitsstandards weltweit.

Das Krankenhaus hat seine Position als führende Marke im Gesundheitssektor des Königreichs und des Nahen Ostens gefestigt und wurde zum zweiten Mal in Folge zur wertvollsten Marke im Gesundheitswesen gekürt. Innerhalb des Königreichs liegt es auf Platz 9 und im Nahen Osten auf Platz 28. Das Krankenhaus zeichnet sich als einziges Krankenhaus weltweit dadurch aus, dass es in die Top 10 der Marken seines Landes aufgestiegen ist, was in zwei Berichten von „Brand Finance“ über die 50 wertvollsten Marken in Saudi–Arabien und die 150 wertvollsten Marken im Nahen Osten im Jahr 2024 hervorgehoben wird.

Dank der Transformationsprogramme und der Vision 2030 des Königreichs, die von Seiner Königlichen Hoheit, dem Kronprinzen und Premierminister – möge Gott ihn beschützen – ins Leben gerufen wurden, um die Führungsrolle des Königreichs im globalen Gesundheitssektor zu stärken, hat sich das KFSH&RC zu einem führenden akademischen medizinischen Zentrum im Nahen Osten und in Afrika entwickelt. Laut „Brand Finance“ bleibt es 2024 zum zweiten Mal in Folge auf Platz 20 der Weltrangliste. Außerdem wurde es von der amerikanischen Zeitschrift „Newsweek“ zu den 250 besten Krankenhäusern weltweit im Jahr 2024 gezählt.

Für weitere Informationen wenden Sie sich bitte an:

Hr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Hr. Abdullah Alown, Media Coordination Officer, 0556294232

Ein Foto zu dieser Mitteilung ist verfügbar unter https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605–9a75–41cb–8947–81c858209621


GLOBENEWSWIRE (Distribution ID 9117305)

King Faisal Specialist Hospital and Research Centre Welcomes New Deputy CEO Amid Strategic Transformations

RIYADH, Saudi Arabia, May 13, 2024 (GLOBE NEWSWIRE) — King Faisal Specialist Hospital and Research Centre (KFSH&RC) has recently welcomed Dr. Björn Zoéga as its Deputy CEO, an appointment that underscores its commitment to promoting and fostering healthcare excellence. Dr. Zoéga, renowned for his extensive experience in healthcare management and policy, joins a dedicated team as the hospital continues to drive key strategic initiatives.

KFSH&RC, a leader in medical research and clinical services, continues to attract global expertise to bolster its vision of healthcare excellence. With Dr. Zoéga's involvement, the hospital is advancing a digital transformation strategy designed to improve operational efficiency and enhance patient care. His expertise in fostering international collaborations, evidenced by his former role as president of the European University Hospital Alliance (EUHA) and through initiatives like JOIN4ATMP aimed at advancing access to innovative therapies, further aligns KFSH&RC's services with global healthcare trends.

Key projects at KFSH&RC include the deployment of advanced digital technologies to streamline the patient care process, the adoption of innovative care models, and the upgrading of facility amenities. These strategic efforts aim to improve access to medical services and facilitate better communication, reflecting KFSH&RC's dedication to setting new standards in healthcare.

Dr. Zoéga's previous contributions at Karolinska University Hospital, which is ranked the second best in Europe and seventh globally by Newsweek's 2024 World's Best Hospitals, where he nurtured a culture of continuous learning and collaboration among healthcare professionals, align well with KFSH&RC's objectives. His role in fostering programs like EUCARE and facilitating the Europe–wide exchange of intensive care nurses during crises has significantly enhanced staff development and supported his previous hospital's goal of attracting top talent—a principle mirrored in KFSH&RC's transformation journey. With Dr. Zoéga contributing to leadership, KFSH&RC is poised to further its role as a pivotal player in shaping the future of healthcare in Saudi Arabia.

About King Faisal Specialist Hospital and Research Centre:

King Faisal Specialist Hospital & Research Centre stands among the global leaders in providing specialized healthcare, driving innovation, and serving as an advanced medical research and education hub. Through strategic partnerships with prominent local, regional, and international institutions, the hospital is dedicated to advancing medical technologies and elevating healthcare standards worldwide.

The hospital has secured its position as the leading brand in the healthcare sector across the Kingdom and the Middle East, marking its second consecutive year as the most valuable healthcare brand. It ranks 9th within the Kingdom and 28th in the Middle East. The hospital distinguishes itself as the sole hospital globally to break into the top 10 brands in its country, as highlighted in two reports by “Brand Finance” on the 50 most valuable brands in Saudi Arabia and the 150 most valuable brands in the Middle East in 2024.

Due to the transformation programs and the Kingdom’s Vision 2030, launched by His Royal Highness the Crown Prince and Prime Minister – may God protect him – to enhance the Kingdom’s leadership in the global healthcare sector, KFSH&RC has emerged as a leading Academic Medical Centre in the Middle East and Africa. It maintained its 20th rank globally for the second consecutive year in 2024, according to “Brand Finance.” Additionally, it has been ranked among the top 250 hospitals globally in 2024 by the American magazine “Newsweek.”

For further information, please contact:

Mr. Essam AlZahrani, Acting Head of Media Affairs, 0555254429

Mr. Abdullah Alown, Media Coordination Officer, 0556294232

 

A photo accompanying this announcement is available at https://www.globenewswire.com/NewsRoom/AttachmentNg/83d04605–9a75–41cb–8947–81c858209621

 


GLOBENEWSWIRE (Distribution ID 9116335)